14 active not recruiting. 14 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 14 |
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer Capecitabine, Toripalimab - Gallbladder Cancer, Hilar Cholangiocarcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 110 | 2024-11-12 | 2024-12-05 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer SOC plus trastuzumab and pembrolizumab - Biliary Tract Cancer, HER2 Gene Mutation | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 24 | 2024-04-17 | 2026-03-27 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Compass Therapeutics | 168 | 2023-01-09 | 2026-09-02 |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy - Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 186 | 2021-02-24 | 2026-10-19 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers tucatinib, trastuzumab, oxaliplatin - Colorectal Carcinoma, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 40 | 2020-09-15 | 2026-02-24 |
| Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer Durvalumab + Gem/Cis, Gem/Cis - Biliary Tract Neoplasms, Gallbladder Cancer | Phase 2 | Active not recruiting | Asan Medical Center | 45 | 2020-05-20 | 2025-01-28 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Gemcitabine, Cisplatin, Chemoradiation - Gall Bladder Cancers | Phase 2 / Phase 3 | Active not recruiting | Tata Memorial Hospital | 124 | 2016-09-06 | 2025-03-13 |
| A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Selumetinib, Cisplatin, Gemcitabine - Biliary Tract Carcinoma, Gallbladder Carcinoma | Phase 2 | Active not recruiting | University Health Network, Toronto | 57 | 2014-11-01 | 2026-06-22 |
Cholangiocarcinoma (10) · Biliary Tract Neoplasms (4) · Thyroid Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Carcinoma, Adenoid Cystic (2) · Carcinosarcoma (2) · Colorectal Neoplasms (2) · Hemangiosarcoma (2) · Klatskin Tumor (2) · Neurofibrosarcoma (2) · Parathyroid Neoplasms (2) · Stomach Neoplasms (2) · Vulvar Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1)
Biliary Tract Diseases (14) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Gallbladder Diseases (14) · Neoplasms (14) · Neoplasms by Site (14) · Adenocarcinoma (11) · Carcinoma (11) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Biliary Tract Neoplasms (10) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Head and Neck Neoplasms (4) · Adnexal Diseases (3)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Biopsy (3) · Cisplatin (3) · Gemcitabine (3) · Capecitabine (2) · Fluorouracil (2) · Leucovorin (2) · Nivolumab (2) · Oxaliplatin (2) · Trastuzumab (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · AZD 6244 (1) · CTLA-4 Antigen (1)
National Cancer Institute (NCI) (4) · Arvinas Inc. (1) · Asan Medical Center (1) · Compass Therapeutics (1) · ECOG-ACRIN Cancer Research Group (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Instituto do Cancer do Estado de São Paulo (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · Tata Memorial Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University Health Network, Toronto (1)
United States (8) · Brazil (1) · Canada (1) · China (1) · Germany (1) · Guam (1) · India (1) · Japan (1) · South Korea (1)
Ardaman Shergill (1) · Camila MV Moniz, Doctor (1) · Changhoon Yoo, MD, PhD (1) · Cynthia Sirard, MD (1) · Jennifer Knox, M.D. (1) · Kristen R Spencer (1) · Nilofer S Azad (1) · Reena Engineer, MBBS MD (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Sandip P Patel (1) · Shishir K Maithel (1)
PMID 31253621, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 38861293, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
2025 (1), U10CA180820 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186691 (1), UM1CA186716 (1)